Core Viewpoint - Pulmatrix, Inc. is focusing on advancing its proposed merger with Cullgen while also seeking to license or monetize its iSPERSE™ technology and related clinical programs, particularly in the context of its financial results for the year-end and fourth quarter of 2025 [1][2]. Financial Performance - Revenues for the year ended December 31, 2025, decreased to $0 from $7.8 million in 2024, primarily due to the wind down of the PUR1900 program [2]. - Research and development expenses dropped to less than $0.1 million in 2025 from $7.2 million in 2024, attributed to the cessation of the PUR1900 Phase 2b clinical trial and related operational reductions [2]. - General and administrative expenses decreased to $5.1 million in 2025 from $7.8 million in 2024, reflecting lower employment and operational costs [2]. - The total cash and cash equivalents as of December 31, 2025, were $4.1 million, down from $9.5 million in 2024, with expectations to fund operations into the first quarter of 2027 [2]. Proposed Merger with Cullgen - Pulmatrix entered into a merger agreement with Cullgen on November 13, 2024, with subsequent amendments, and is currently awaiting approval from the China Securities Regulatory Commission (CSRC) [1]. - The merger agreement includes a waiver of the "No Solicitation" clause, allowing both companies to explore alternative transactions while pursuing merger approval [1][2]. iSPERSE™ Technology and Clinical Programs - Pulmatrix's iSPERSE™ technology includes approximately 149 granted patents and 48 pending applications, aimed at improving drug delivery for respiratory diseases [1]. - The company is advancing its clinical programs, including PUR3100, which is ready for Phase 2 trials for acute migraine treatment, and PUR1800, which is being developed for chronic obstructive pulmonary disease [1][2]. - PUR1900, an inhaled formulation of itraconazole, is in Phase 3 trials in India, with Pulmatrix receiving 2% royalties on future net sales outside the U.S. [1][2].

Core Viewpoint - Cipla has launched Afrezza, a rapid-acting inhaled insulin, in India, providing a needle-free alternative to traditional injectable insulin therapy [1][2]. Product Details - Afrezza is an inhalation powder that dissolves quickly upon oral inhalation, beginning to lower blood glucose levels within approximately 12 minutes, mimicking the body's natural insulin response [2]. - The product will be available in single-use cartridges and delivered through an inhaler device, making the process of inhaling insulin straightforward [3]. Target Audience and Benefits - The inhaled insulin is designed for adults with type-1 and type-2 diabetes mellitus, aiming to improve adherence to therapy and enable quicker glycemic control [5]. - It addresses emotional and practical barriers that often lead patients to delay or discontinue insulin therapy [5]. Health Considerations - The product is not advisable for individuals with pulmonary concerns such as asthma or chronic obstructive pulmonary disease (COPD) [4].

Group 1 - Halper Sadeh LLC is investigating Vital Energy, Inc. for potential violations related to its sale to Crescent Energy Company, where shareholders will receive 1.9062 shares of Crescent Class A common stock for each share of Vital common stock [1] - scPharmaceuticals Inc. is being investigated for its sale to MannKind Corporation, offering shareholders a cash payment of $5.35 per share plus a non-tradable contingent value right (CVR) worth up to $1.00 per CVR upon achieving specific milestones [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. to MannKind Corporation for $5.35 per share in cash, plus a contingent value right offering milestone-based payments of up to $1.00 per share [1][3]. Summary by Relevant Sections Sale Details - scPharmaceuticals, Inc. has agreed to be sold to MannKind Corporation for $5.35 per share in cash, along with a non-tradable contingent value right that offers milestone-based payments of up to $1.00 per share [1][3]. Price Evaluation - The sales price of $5.35 per share is below the price targets set by multiple Wall Street analysts prior to the announcement, indicating potential undervaluation [2][3]. - Analysts' price targets include $25.00 by TD Cowen, $18.00 by H.C. Wainwright, $13.00 by Jefferies, and $12.00 by Craig-Hallum [5]. Investigation Rationale - The investigation aims to determine whether the SCPH Board of Directors acted in the best interests of shareholders and if the agreed price is fair, along with the completeness of material information disclosed regarding the transaction [3].

Financial Data and Key Metrics Changes - Fourth quarter revenues were $77 million, a 31% increase over the previous year's fourth quarter [35] - Full year revenues reached $286 million, a 43% increase compared to the prior year [35] - Net income for 2024 was $28 million, or $0.10 per share, compared to a net loss of $12 million, or $0.04 per share for 2023 [41] - The year-end cash position was $203 million, with a debt reduction of $236 million in 2024 [42] Business Line Data and Key Metrics Changes - The endocrine business unit achieved record revenues of $23 million in Q4 and $82 million for the full year [6] - Afrezza net revenue for Q4 was $18 million, an 18% increase, and $64 million for the full year, a 17% increase [37] - V-Go net revenue was approximately $5 million for Q4, a 1% increase, but full year revenues decreased by 4% to $18 million [38] Market Data and Key Metrics Changes - Tyvaso DPI royalties contributed $27 million in Q4, a 28% increase, and $102 million for the year, a 42% increase [36] - DPI-related revenues exceeded $200 million for the year, marking a significant milestone for the Technosphere platform [18] Company Strategy and Development Direction - The company focuses on five key pillars, including two FDA-approved products and funding for pipeline opportunities [5] - The strategy includes expanding the pediatric market for Afrezza and exploring gestational diabetes [11][14] - The company aims to leverage its strong balance sheet to support growth and pipeline development [42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for significant growth in the pediatric market for Afrezza [15] - The company is preparing for upcoming FDA meetings and expects to advance its pipeline projects [33][45] - Management emphasized the importance of effective reimbursement and education strategies for successful product launches [72][75] Other Important Information - The company successfully reduced its debt and improved its cash position, providing a strong foundation for future growth [42] - The collaboration with Amphastar is expected to enhance the pediatric footprint and expedite the filing for pediatric indications [7] Q&A Session Summary Question: Can you talk about margins over the next few quarters? - Management indicated that margins are expected to stabilize as manufacturing utilization increases with Tyvaso DPI and Afrezza [52] Question: Can you provide more details on gross to net discounting and rebates? - Management noted that the current discounting trends are expected to continue throughout the year [54] Question: How do you balance operational profitability with investment in Afrezza? - Management stated that capital deployment will focus on driving the best returns for shareholders while preparing for the pediatric launch [60] Question: What are the critical success factors for Afrezza in pediatrics? - Management identified reimbursement processes, institutional selling capabilities, and education as key factors for success [71][75] Question: What are the expectations for the agreement with CIPLA in India? - Management anticipates that the agreement could lead to significant volume implications and improve overall efficiency [78] Question: What are the safety and efficacy endpoints for the upcoming FDA meeting? - Management plans to discuss various endpoints and trial designs with the FDA, aiming for a solid foundation for future milestones [86][88]